by Paul Winner | Sep 18, 2019 | Migraines
A novel treatment option for acute migraine that is currently under review by the Food and Drug Administration (FDA) has shown promising results in the reduction of pain and disability in acute migraine sufferers. The drug ubrogepant, developed by Allergen, is a small...
by Paul Winner | Jul 21, 2019 | Migraines
Over the past decade, there has been a significant amount of progress made in the development of new preventative migraine therapies that differ from previous treatment types. One such breakthrough was the recent FDA approval of medications in a novel class of drugs...
by Paul Winner | Jan 15, 2019 | Migraines
A new and unique class of preventive migraine treatments have been approved by the FDA over the past year which have several benefits over older medications for the prevention of migraine. Anti-CGRP medicines, which are monoclonal antibodies, block the activity of...
by Paul Winner | Sep 25, 2018 | Migraines
A new small molecule calcitonin gene-related peptide (CGRP) drug in phase 3 clinical trials has shown promising relief of migraine symptoms when administered as an acute single-dose treatment. The migraine drug, Rimegepant, relieved pain and other bothersome migraine...
by Paul Winner | Jul 5, 2018 | Migraines
Adults with migraine now have an additional preventative treatment option available to them, thanks to a new and unique migraine medication that has been approved by the Food and Drug Administration (FDA). Aimovig (erenumab-aooe) is a novel, first of its kind...
